Skip to main content

Table 2 Multinomial logistic regression for the association of CTRP5 (a) WC (b) hip (e), WHR (h) and BMI (k) with outcome risk of NAFLD, T2DM, and NAFLD + T2DM

From: The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study

Groups

B

SE

Wald

p value

Odds ratio

95 % confidence interval for OR

Correct prediction (%)

a. Risk of outcomes along with each unit increase in CTRP5

 NAFLD

−6.495

0.036

32,216.808

<0.001

0.00151

0.00141–0.00162

40.9

 T2DM

−6.571

0.039

28,394.414

<0.001

0.00140

0.00130–0.00151

66.7

 NAFLD + T2DM

−6.531

0

–

–

0.00146

0.00146–0.001461

26.1

b. Risk of outcomes along with each unit increase in WC

 NAFLD

0.126

0.038

10.756

0.001

1.134

1.052–1.223

22.7

 T2DM

0.071

0.033

4.612

0.032

1.074

1.006–1.146

27.3

 NAFLD + T2DM

0.191

0.044

18.743

<0.001

1.210

1.110–1.319

54.5

c. Adjustment of CTRP5 risk for WC†

 NAFLD

−6.486

0.039

28,258.994

<0.001

0.00152

0.00141–0.00164

47.6

 T2DM

−6.555

0.043

23,663.923

<0.001

0.00142

0.00130–0.00154

52.4

 NAFLD + T2DM

−6.522

<0.001

–

–

0.001

0.001–0.001

47.4

d. Interaction risk (CTRP5 × WC) for each unit increase in CTRP5 and each unit increase of WC†

 NAFLD

0.0

0.0

11.289

0.001

0.999

0.99–1

52.4

 T2DM

−0.001

0.0

20.162

<0.001

0.999

0.98–0.99

57.1

 NAFLD + T2DM

0.0

0.0

8.270

0.004

0.999

0.99–1

10.5

e. Risk of outcomes along with each unit increase in hip

 NAFLD

0.169

0.058

8.403

0.004

1.184

1.056–1.327

18.2

 T2DM

0.037

0.049

0.587

0.444

1.038

0.943–1.143

22.7

 NAFLD + T2DM

0.246

0.065

14.306

<0.001

1.279

1.126–1.453

54.5

f. Adjustment of CTRP5 risk for hip†

 NAFLD

−4.922

0.038

16,351.610

<0.001

0.00728

0.00675–0.00785

47.6

 T2DM

−4.994

0.043

13,373.185

<0.001

0.00677

0.00622–0.00737

52.4

 NAFLD + T2DM

−4.953

0

–

<0.001

0.00706

0.00706–0.00706

42.1

g. Interaction risk (CTRP5 × hip) for each unit increase in CTRP5 and each unit increase of hip †

 NAFLD

−0.002

0.0005

13.028

<0.001

0.9983

0.9974–0.9992

66.7

 T2DM

−0.003

0.001

23.169

<0.001

0.9974

0.9964–0.9984

61.9

 NAFLD + T2DM

−0.0002

0.0005

13.013

<0.001

0.9983

0.9973–0.9992

0

h. Risk of outcomes along with each unit increase in WHR

 NAFLD

17.519

6.128

8.171

0.004

40,570,699.7

246.43–6.67 × 1012

63.6

 T2DM

16.808

6.191

7.372

0.007

19,938,468.5

107.2–3.7 × 1012

0

 NAFLD + T2DM

24.517

6.609

13.760

<0.001

44,428,129,710.6

105147.7–1.8 × 1016

57.1

i. Adjustment of CTRP5 risk for WHR†

 NAFLD

−6.519

0.039

28,193.410

0.001

0.00147

0.00136–0.00159

61.9

 T2DM

−6.588

0.041

25,291.299

0.001

0.00137

0.00126–0.00149

42.1

 NAFLD + T2DM

−6.559

<0.001

–

–

0.00141

0.00141–0.00141

38.9

j. Interaction risk (CTRP5 × WHR) for each unit increase in CTRP5 and each unit increase of WHR†

 NAFLD

−0.161

0.043

14.026

<0.001

0.851

0.783–0.926

61.9

 T2DM

−0.193

0.046

17.424

<0.001

0.824

0.753–0.903

52.6

 NAFLD + T2DM

−0.151

0.043

12.6

<0.001

0.860

0.791–0.935

0

k. Risk of outcomes along with each unit increase in BMI

 NAFLD

0.338

0.101

11.155

0.001

1.403

1.150–1.711

31.8

 T2DM

0.173

0.087

3.976

0.046

1.189

1.003–1.409

27.3

 NAFLD + T2DM

0.500

0.117

18.150

<0.001

1.648

1.310–2.074

63.6

l. Adjustment of CTRP5 risk for BMI levels†

 NAFLD

−4.243

0.038

12,261.550

<0.001

0.0144

0.0133–0.0155

47.6

 T2DM

−4.308

0.043

10,259.458

<0.001

0.0134

0.0124–0.0146

57.1

 NAFLD + T2DM

−4.283

<0.001

–

–

0.0138

0.0138–0.0138

57.9

m. Interaction risk (CTRP5 × BMI) for each unit increase in CTRP5 and each unit increase of BMI

 NAFLD

−0.001

0.001

5.166

0.023

0.999

0.997–1.000

57.1

 T2DM

−0.003

0.001

14.793

<0.001

0.997

0.996–0.999

61.9

 NAFLD + T2DM

0.000

0.001

2.864

0.091

0.999

0.998–1.000

0

  1. Adjustment for risk of CTRP5 for the aforesaid outcome diseases by controlling for WC (c) hip (f), WHR (i) and BMI (l) The interactive risk of increasing CTRP5 levels with WC (d) hip (g), WHR (j) and BMI (m) for the aforesaid outcome diseases
  2. NAFLD non-alcoholic fatty liver disease, T2DM type 2 diabetes mellitus, CTRP5 complement-C1q TNF-related protein 5, BMI body mass index, WC waist circumference, WHR waist-to-hip ratio
  3. †Likelihood Ratio Test: p value < 0.0001
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us